NanoViricides, Inc. (NNVC)

NYSEAMERICAN: NNVC · IEX Real-Time Price · USD
2.30 -0.25 (-9.80%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap26.51M
Revenue (ttm)n/a
Net Income (ttm)-9.12M
Shares Out11.53M
EPS (ttm)-0.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume140,120
Open2.55
Previous Close2.55
Day's Range2.25 - 2.55
52-Week Range2.25 - 8.71
Beta0.59
AnalystsStrong Buy
Price Target8.75 (+280.4%)
Earnings Daten/a

About NNVC

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-In...

IndustryBiotechnology
Founded2005
Employees17
Stock ExchangeNYSEAMERICAN
Ticker SymbolNNVC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for NanoViricides stock is "Strong Buy" and the 12-month stock price forecast is 8.75.

Price Target
$8.75
(280.43% upside)
Analyst Consensus: Strong Buy

News

NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug...

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanome...

2 months ago - Accesswire

EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment

NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. The company believes the form...

2 months ago - Benzinga

NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-...

SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicine...

2 months ago - Accesswire

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage

SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021 ...

3 months ago - Accesswire

NanoViricides: There Is More to Come

NanoViricides Inc. ( NNVC , Financial) is one of the emerging biotech companies that I have been following for a while now. Its stock price had more than doubled last month after a major update from the...

3 months ago - GuruFocus

NanoViricides COVID-19 Treatment Candidate Found Effective Against Coronavirus Variants In Lab Study

Shares of NanoViricides Inc (NYSE: NNVC), a developer of antiviral therapies based on a novel nanomedicines technology, are higher Monday. What Happened: NanoViricides said its pan-Coronavirus COVID-19 ...

3 months ago - Benzinga

NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstra...

Shelton, Connecticut -- (October 11, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

3 months ago - Benzinga

NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstra...

SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

3 months ago - Accesswire

NanoViricides Leaps Forward in its Quest to Defeat COVID-19

Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19. The good news is they suc...

3 months ago - Benzinga

NanoViricides: Why Has the Stock Doubled?

There were a large number of pharma companies of all sizes that began their research on developing both drugs as well as vaccines to counter the SARS-CoV-2 since 2019. Some of these companies have succe...

4 months ago - GuruFocus

Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Dru...

SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicin...

4 months ago - PRNewsWire

NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?

A Covid-19 treatment producer halted trading this morning, but news has revealed that NNVC stock is still moving upward. The post NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?

4 months ago - InvestorPlace

Nanoviricides Stock Surges, Nears The End Of A Pennant Pattern

Nanoviricides Inc. (NYSE:NNVC) shares are surging higher Tuesday following news of the company reporting significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thu...

4 months ago - Benzinga

What Is a ‘News Pending' Halt? What to Know as NNVC Stock Captivates Investors

Today, NanoViricides is grabbing a lot of attention due to a news pending halt that has sent NNVC stock skyrocketing. The post What Is a ‘News Pending' Halt?

4 months ago - InvestorPlace

NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development

SHELTON, Conn., Sept. 14, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.

4 months ago - PRNewsWire

NanoViricides Review: What you Need to Know About the Company

With the coronavirus changing the world in 2020, it makes sense that there's a spotlight on science to prevent viruses from growing into pandemics. While Pfizer (NYSE: PFE) and Moderna Inc. (NASDAQ: MRN...

7 months ago - Benzinga

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Can...

SHELTON, CT / ACCESSWIRE / May 17, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicin...

8 months ago - Accesswire

NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in S...

SHELTON, CT / ACCESSWIRE /  March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines ...

10 months ago - Accesswire

NanoViricides Jumps On 'Strong Pan-Coronavirus Effectiveness' From 2 COVID-19 Candidates In Lab Studies

Shares of nano-cap biopharma NanoViricides, Inc. (NASDQ: NNVC) were trading solidly higher Tuesday following a positive data readout. What Happened: Two NanoViricides COVID-19 clinical drug candidates —...

10 months ago - Benzinga

NNVC Stock: The COVID-19 Drug News That Has NanoViricides Rocketing Today

NanoViricides (NNVC) stock is on the rise Tuesday after revealing results from the company's drug candidates to treat the coronavirus. The post NNVC Stock: The COVID-19 Drug News That Has NanoViricides ...

10 months ago - InvestorPlace

NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pr...

SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine tech...

10 months ago - Accesswire

NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19

NanoViricides Inc (NYSE: NNVC) has reported data from animal studies evaluating its broad-spectrum antiviral drug candidate NV-CoV-2 to treat COVID-19 infections.  The treatment candidate was well toler...

11 months ago - Benzinga

Small Caps Daily Features NanoViricides' Rapid Advancement to Clinical Trials for its COVID-19 Therapy

New York, New York--(Newsfile Corp. - November 18, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a...

1 year ago - Newsfile Corp

NanoViricides: One Step at a Time

As the confirmed Covid-19 death toll nears the 1.3 million mark, pharma and biotech companies all over the world are making progress in their attempts to develop a cure for the disease.

1 year ago - GuruFocus

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NanoViricides, Inc. and Encoura...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NanoViricides, Inc. (“NanoViricides” or “the Company”) (NYSE: NNVC...

1 year ago - Business Wire